Business
Isodiol International Inc. Set to Debut New CBD Beverage Ingredient, Heneplex p200™, at Supply Side West and Provides Shareholder Update
Isodiol International Inc. Set to Debut New CBD Beverage Ingredient, Heneplex p200™, at Supply Side West and Provides Shareholder Update.
About this update from Isodiol International Inc
[{"type":"text","content":"\nIsodiol introduces new CBD raw ingredient, Heneplex p200™, to meet the demand for CBD Beverages as mainstream retailers prepare for the anticipated approval of the U.S. Hemp Bill. \n VANCOUVER, British Columbia, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE: ISOL) (OTCQB: ISOLF) (FSE: LB6B.F) (the “Company” or “Isodiol”) is set to debut its newest CBD raw ingredient, Heneplex p200™, at Supply Side West in Las Vegas November 8th and 9th, 2018, booth 1557, to meet the new demand and market trend in the beverage sector. Heneplex p200™ has the advantage of being far more versatile than traditional CBD hemp extracts and oils, which can be difficult to formulate and use to manufacture consumer good products. CBD hemp extract in an oil form sticks to just about everything, tastes bad to many users, and dissolves in few substances besides alcohols and oils. In short, formulating with CBD hemp extracts is challenging. p200™ by contrast, can simply be mixed into food and beverage products, almost without exception, including protein shakes, juices, soda, coff­ee, tea, baked goods or frozen goods, or simply added to a glass of water. Management would also like to provide an update to its shareholders around the volatility of the stock and would like to address recent investor inquiries. The Company has not deviated from its business plan announced on June 29, 2018 and believes it is executing on its business strategies in each division with new revenue opportunities being added on a consistent basis. Further, management believes some of the Company’s business strategies are in front of market trends that will soon be recognized by the market, particularly as legalization continues to trend in a favourable direction in the United States and Mexico. Due to recent developments with the US Hemp Bill, the Company has postponed plans of its previously announced Chinese facility expansion plans and has been focusing its resources and attention to the expected upcoming opportunities in the United States and Mexico. On December 6, 2017, the Company announced the 100% acquisition of CN Pharma, located in Abbotsford, BC, a pharmaceutical manufacturing company. The Company believed that CN Pharma was in the latter stages of obtaining its Licensed Dealer (“...